Clinical trials: Urinary Urgency Incontinence
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder, Urge Urinary Incontinence
Pelvic Floor Muscle Training With Leva System for Urge Incontinence
This is a pilot non-comparative study to assess the effectiveness of pelvic floor muscle training guided by the leva® system for improving change in subject-reported incontinence-related quality of life and urgency urinary…
- Conditions
- Overactive Bladder, Urge Urinary Incontinence, Mixed Urinary Incontinence
- Trial name
- NCT03923348
- Testing
- Leva device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Christ Hospital
Urinary Bladder, Overactive
Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence
Pubovaginal sling (PVS) procedures are designed to curtail bladder leakage brought about by strenuous events such as child birth.
- Trial name
- NCT01194999
- Testing
- Pubovaginal sling procedure
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- Barrie Urology Associates
Urinary Incontinence, Urinary Urge Incontinence
Real-World Registry - The Vivally® System
This is a Real-World Registry Study to collect real-world dosing, utilization, demographic, quality of life, and data from the e-bladder diaries of patients utilizing the Vivally® System.
- Trial name
- NCT06085846
- Testing
- Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Avation Medical, Inc.
Urologic Diseases, Urinary Bladder Diseases
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
- Conditions
- Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms
- Trial name
- Symphony (NCT01340027)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 133 sites in Belarus, Belgium and 18 more
- Volunteers
- 1,307 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Urgency Urinary Incontinence
Sacral Neuromodulation and the Microbiome
Sacral neuromodulation (SNM) which is approved as a treatment for men and women with urgency urinary incontinence (UUI), urgency frequency syndrome, urinary retention and anal incontinence, is a procedure designed to deliver…
- Trial name
- NCT02833402
- Testing
- InterStim Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Overactive Bladder, Urge Incontinence
Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence
Overactive bladder (OAB) affects an estimated 16-30% of women in the US and urgency urinary incontinence (UUI) affects 7-11% of women with OAB.
- Trial name
- NCT05099419
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Overactive Bladder
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)
The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling…
- Trial name
- OVADER (NCT04545580)
- Testing
- BAY1817080
- Where
- 28 sites in Australia, Austria and 7 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Urge Incontinence, Urgency-frequency Syndrome
The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function
This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.
- Trial name
- NCT05391425
- Testing
- no intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Istanbul University
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Overactive Bladder, Urinary Urgency
Group Medical Visits for Latina Women With Urgency Urinary Incontinence
This is a mixed methods study to compare group medical visits (GMVs) to usual care for Spanish speaking Latina women with urgency urinary incontinence. Patients will be randomized to GMVs and to usual care.
- Conditions
- Overactive Bladder, Urinary Urgency, Urge Incontinence
- Trial name
- NCT03687164
- Testing
- Group Medical Visits
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Southern California
Urinary Incontinence, Urge, Urinary Incontinence
TReating Incontinence for Underlying Mental and Physical Health
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder…
- Conditions
- Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder, Incontinence, Urge
- Trial name
- TRIUMPH (NCT05362292)
- Testing
- Tolterodine Tartrate ER, Mirabegron
- Where
- 2 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Overactive Bladder
Add-On ZIDA Sock Therapy for Overactive Bladder
Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild…
- Trial name
- NCT07432659
- Testing
- ZIDA Control Sock
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Urinary Bladder, Overactive
A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder
The purpose of this study is to explore additional benefit of solifenacin after 12-week treatment, compared with alpha blocker monotherapy in men with residual OAB symptoms.
- Trial name
- NCT00699049
- Testing
- Alpha blocker, solifenacin
- Where
- 3 sites in South Korea
- Volunteers
- 94 people
- Sponsor
- KYU-SUNG LEE
Overactive Bladder
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT01004315
- Testing
- KUC-7483, Tolterodine
- Where
- Japan
- Volunteers
- 750 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Urge Incontinence, Overactive Bladder
Transcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence
This is a single-center, double-blinded, randomized controlled trial evaluating the efficacy of TTNS versus a sham intervention. Both interventions will be performed by participants in their homes after standardized instruction.
- Trial name
- TTeNS (NCT04936464)
- Testing
- transcutaneous tibial nerve stimulation (TTNS), transcutaneous electrical stimulation (TENS)
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Kaiser Permanente
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome
- Trial name
- NCT04500860
- Testing
- Low dose tadalafil 5 mg, Tolterodine 4 Mg Oral Capsule, Extended Release
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Kasr El Aini Hospital